Novavax (NASDAQ: NVAX) was one of the early stars of the coronavirus vaccine race. Its shares soared about 2,700% in 2020. That's after it became one of the first to launch clinical trials and the U.S. government invested $1.6 billion in its program.
But the company fell behind in regulatory submissions and entered the market later than rivals Pfizer and Moderna. Right now, more than 35 countries have authorized its vaccine. But it's still waiting for authorization in the U.S. The shares have lost 46% this year, but they've rebounded 87% over the past month. Should you avoid this vaccine player? Or is it time to buy? Let's look at the bear and bull cases.
Novavax missed out on the first wave of coronavirus vaccinations. This probably was the time when the most money could have been made. That's because need was at its highest. No one had yet been vaccinated, so people flocked to vaccination centers as soon as they opened.
Source Fool.com